Information Library
Cost control/reduction - Faster product development
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
QUINTILES ANNOUNCES CLINICAL RESEARCH PARNERSHIP WITH THE UNIVERSITY OF PRETORIA
September 10, 2009 – Quintiles Prime Site Program expands into South Africa to accelerate clinical development. -
Sub-Saharan Africa Phase II/III Fact Sheet
July 29, 2009
Sub-Saharan Africa fact sheet about Phase II/III trials. The gateway to Africa: Access to expanded clinical resources and patient populations in South Africa and beyond. -
Phase One Services: Dr. Brock G. Guernsey
July 24, 2009
Why wait two months to see your data and delay critical decisions when we can deliver your data within a week using electronic bedside data entry? Consider what a 2-month delay means to your drug's development plan? Whether you've done preclinical work and need a rapid Proof of Concept study or are looking for a benchmark of how your drug performs in a specific disease state, we can help. -
Phase One Services: Dr. Elizabeth Allen
July 24, 2009
In 2008 TUFTS reported that it costs over $1 billion to develop a new biopharmaceutical product. Half of this investment occurs in the later stages of testing. Thankfully at Quintiles, we provide accurate and correct Phase I and IIa data quickly. We can help you make smart, safe decisions earlier to avoid repeating costly studies later. -
Phase One Services: Dr. Philip T. Leese
July 24, 2009
At Quintiles, we appreciate the data collection from the clinic as one of the most important parts of a study process. To deliver quality data on time, we ensure that all clinical conduct is consistent, efficient and accurate to your protocol. But to do this we also need to recruit the right volunteers. Our database of clearly defined volunteers means we can quickly call upon participants for student specific screening, saving you time and money. What's more, we also use a range of recruitment methods to keep the database up to date with interested volunteers. -
Phase One Services: Professor Timothy G.K. Mant
July 24, 2009
You can only have total confidence in the integrity and analysis of results of you're sure your study has been conducted in exceptional clinical conditions. So it's absolutely crucial that your Phase I/IIa partner places ethics, safety and expert clinical conduct at the heart of all their activities. -
Clinical Development Services
June 18, 2009
Find out how large pharmaceutical companies and emerging biotech move products past each development milestone. -
Jim Featherstone, Ph.D.
March 25, 2009
Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice. -
Matthew Eberhart
March 25, 2009
Matt is a proven business-building executive with a strong track record of implementing successful business development initiatives for consulting healthcare companies in both North America and Europe. -
Antibiotic Safety Assessment
March 25, 2009
A major pharmaceutical company presented Quintiles with a pressing challenge – to collect extensive amounts of Phase IV data in compressed time windows because the treatment conditions were subject to seasonal variants.
Page 1 of 1 (10 items)